The MMRC Project Review Committee assists the MMRC Steering Committee with the selection and prioritization of the MMRC’s pre-clinical and clinical research efforts. This advisory committee is comprised of one representative from each MMRC Member Institution.

		Kenneth Anderson, MD Chief, Division of Hematologic Neoplasia Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Dr. Anderson graduated from Johns Hopkins Medical School. He trained in internal medicine at Johns Hopkins Hospital and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School and serves as Chief of the Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at the Dana-Farber Cancer Institute. He received the Waldenstrom's Award in 2003 for his translational research directed to the development of novel therapeutics targeting the myeloma cell in its microenvironment. He serves as Chair of the National Comprehensive Cancer Network's Multiple Myeloma Clinical Practice Guidelines Committee, on the Board of Directors and as Chairman of the Scientific Advisors of the Multiple Myeloma Research Foundation, and is a Doris Duke Distinguished Clinical Research Scientist. Dr. Anderson is a founding member of the Multiple Myeloma Research Consortium.
		Bill Dalton, MD, PhD Chief Executive Officer and Center Director H. Lee Moffitt Cancer Center & Research Institute Dr. Dalton received his PhD in toxicology and medical life sciences and his degree in medicine from Indiana University. He completed his internship in internal medicine at Indiana University and his residency in medicine at the University of Arizona in Tucson. Dr. Dalton was the Founding Director of the Bone Marrow Transplant Program at the University of Arizona. From 1997 to 2001, he was Deputy Director of the H. Lee Moffitt Cancer Center & Research Institute and the Chairman of the Department of Interdisciplinary Oncology at the University of South Florida. He served as Dean of the College of Medicine at the University of Arizona in Tucson from 2001 to 2002. In August 2002, Dr. Dalton was appointed the Chief Executive Officer and Center Director of H. Lee Moffitt Cancer Center & Research Institute. Dr. Dalton's research interests include biochemical mechanisms of drug resistance and new drug discovery in multiple myeloma. Dr. Dalton is a founding member of the Multiple Myeloma Research Consortium.
		Sherif Farag, MD, PhD Associate Professor Indiana University School of Medicine Dr. Farag earned his medical degree and PhD from the University of Melbourne, Melbourne, Australia, and completed his fellowship in hematology and oncology at the Roswell Park Cancer Institute. Dr. Farag is Assistant Professor of Medicine and Medical Director of the Stem Cell Transplant Laboratory at the Ohio State University’s Comprehensive Cancer Center. His clinical practice is dedicated to the treatment of lymphoma and multiple myeloma and his research focuses on lymphoma, leukemia and myeloma, the new frontier of stem cell transplantation’s possible role in treatment of those diseases, and ways to make autologous bone marrow transplantation more successful.
		Craig Hofmeister, MD Assistant Professor of Medicine Ohio State University Comprehensive Cancer Center Craig Hofmeister, MD, is Assistant Professor of Medicine at Ohio State University Comprehensive Cancer Center. Dr. Hofmeister received his medical degree from the Ohio State University and completed his internship, residency, and fellowship training at Loyola University Medical Center and Loyola Cardinal Bernardin Cancer Center in Illinois. He is board certified in Internal Medicine, Hematology and Medical Oncology. Dr. Hofmeister's clinical and research interests include multiple myeloma and blood and marrow transplantation.
		Sundar Jagannath, MD Chief of the Multiple Myeloma Service Saint Vincent's Comprehensive Cancer Center Dr. Jagannath received his medical degree at Maharaja Sayajirao University in Baroda, India, and continued his medical training with a fellowship in Immuno-Virology at McMaster University Medical Center in Hamilton, Ontario, Canada. He completed his residency at The Bronx-Lebanon Hospital in Bronx, New York, and Harper-Grace Hospital, Wayne State University, in Detroit, Michigan. Dr. Jagannath also completed a medical oncology fellowship at UTSCC-MD Anderson Hospital and Tumor Institute in Houston, Texas. Dr. Jagannath is Chief of the Multiple Myeloma Service at Saint Vincent's Comprehensive Cancer Center in New York, New York. He is also a Professor of Medicine at New York Medical College and Chief of the Bone Marrow and Blood Stem Cell Transplantation Center at Saint Vincent's Hospital. He is a member of the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and American Society for Bone and Marrow Transplantation.
		Andrzej Jakubowiak, MD, PhD University of Michigan Andrzej Jakubowiak received both his medical and doctoral degrees from the Medical Academy in Pozan, Poland. Prior to joining the faculty of the University of Michigan in 2000, Dr. Jakubowiak completed a fellowship in hematology/oncology from Memorial Sloan-Kettering Cancer Center in New York. His clinical interests are in the treatment of multiple myeloma and other hematological malignancies including Hodgkin’s and non-Hodgkin’s lymphoma, and acute/chronic leukemia. Dr. Jakubowiak’s research focuses on treatment protocols for multiple myeloma and lymphoma.
		Asher Chanan-Khan, MD Attending Physician Department of Medicine Roswell Park Cancer Institute Dr. Chanan-Khan earned his medical degree from the Allama Iqbal Medical College, Punjab University, Pakistan. He completed residency training in internal medicine at the College of Physicians & Surgeons, Columbia University, Harlem Hospital Center, and fellowships in Clinical Hematology and Clinical Oncology at the New York University (NYU) School of Medicine. He is Attending Physician at Roswell Park Cancer Institute and Assistant Professor of Medicine at the University at Buffalo in Buffalo, N.Y. Dr. Chanan-Khan's research interests include novel therapies for multiple myeloma and chronic lymphocytic leukemia. He is a diplomat with the American Board of Internal Medicine and a member of the American Society of Hematology, the American Society of Clinical Oncologists, the American College of Physicians and the American Medical Association.
		Sagar Lonial, MD Associate Professor of Medicine Emory University Dr. Lonial completed his Hematology-Oncology training at Emory University, and prior to that completed his internal medicine residency at the Baylor College of Medicine in Houston, Texas. Dr. Lonial is an Assistant Professor at the Winship Cancer Institute of Emory University, and is also Director of Translational Research, B-cell malignancy program. Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and in the previous years has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. Dr. Lonial’s laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma.
		David Siegel, MD, PhD Division Chief for Myeloma Hackensack University Medical Center Dr. Siegel earned his medical degree from New York University School of Medicine and his doctorate from the Sackler Institute of Biomedical Sciences at New York University's Graduate School of the Arts and Sciences. He completed his internship and residency in internal medicine at New York University-Bellevue Medical Center and his fellowship in hematology/oncology at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Siegel is Division Chief for Myeloma and Lymphoma at the Cancer Center at Hackensack University Medical Center in Hackensack, N.J. He is the recipient of the ASCO Young Investigator Award and a Medical Scientist Training Grant and is a George H. Cook Honors Scholar.
		George Somlo, MD Professor of Medicine Director of the Multiple Myeloma Program City of Hope Medical Center Dr. Somlo received his medical degree from the University of Semmelweiss Medical School, Budapest, Hungary. He completed his residency and internship in internal medicine at the University of California, Irvine and Long Beach, and his fellowship in medical oncology at the City of Hope Medical Center, Duarte, Calif. He is Professor of Medicine and Director of the Multiple Myeloma Program at the City of Hope National Medical Center. His research interests include the role of autologous and allogeneic stem cell transplantation in the treatment of myeloma, identification of molecular targets for myeloma, and incorporation of novel therapeutic agents into the treatment of myeloma.
		A. Keith Stewart, MD Professor Mayo Clinic College of Medicine Dr. Stewart graduated from Medical School at the University of Aberdeen in Scotland. He trained in Internal Medicine at Queen's University in Kingston, Ontario, and specialized in Hematology and Oncology at the University of Toronto, and as a Medical Research Council Fellow at the New England Medical Center in Boston. In 2002, Dr. Stewart also obtained an MBA from Ivey Business School at the University of Western Ontario and was recognized as one of Canada's “Top 40 Under 40.” Dr. Stewart was a consultant at the Toronto General and Princess Margaret Hospitals, University of Toronto, from 1992-2005, where he held the Scott-Whitmore Chair in Hematology. He was appointed the inaugural Director of the McLaughlin Centre for Molecular Medicine at the University of Toronto in 2002. In 2005 Dr. Stewart relocated to the Mayo Clinic -Scottsdale, where he is a Professor of Medicine. He is a member of the Scientific Advisory Board of the Multiple Myeloma Research Foundation and a founding member of the Multiple Myeloma Research Consortium.
		Suzanne Trudel, MD Assistant Professor of Medicine University of Toronto Clinician/Research Scientist Princess Margaret Hospital Dr. Suzanne Trudel is an Assistant Professor of Medicine, in the Division of Hematology at the University of Toronto, and a Clinician/Research Scientist in the Department of Medical Oncology and Hematology at Princess Margaret Hospital/University Health Network. Dr. Trudel received her MD from the Faculty of Medicine at the University of Toronto in 1994. She then completed training in General Internal Medicine and subspecialty training in Hematology at the University of Toronto affiliated hospitals, followed by research training in malignant hematology at Weill Medical College of Cornell in New York. Her research focuses on novel drug development for the treatment of Multiple Myeloma based on molecular targets, and the incorporation of novel treatments into the clinic. Dr. Trudel is a former a former recipient of the American Society of Hematology Scholar Award and holds a Clinician-Scientist Award from the Canadian Institute of Health Research.
		Ravi Vij, MD Assistant Professor of Medicine Washington University Ravi Vij, MD, is Assistant Professor Medicine at Washington University School of Medicine in St. Louis, Mo. He received his medical degree from Maulana Azad Medical College at the University of Delhi in India. He completed residency training in internal medicine at the Rush-Presbyterian-St. Luke's Medical Center in Chicago. He completed fellowships in medical oncology and hematology and bone marrow transplantation/malignant hematology/stem cell biology at Washington University in St. Louis. Dr. Vij’s research interests include multiple myeloma and leukemia. He is a reviewer for several journals, including Blood, Bone Marrow Transplantation, Journal of Clinical Oncology, and Experimental Hematology.
		Jeffrey Wolf, MD Professor of Medicine Director of the Myeloma Program University of California, San Francisco Jeffrey Wolf, MD, is Professor of Medicine, Director of Clinical Research for Hematologic Malignancy, and Director of the Myeloma Program at University of California, San Francisco. Dr. Wolf received his medical degree from the University of Illinois Medical Center and completed his internship and residency at the University of California, San Diego. He has held fellowships at the Fred Hutchinson Cancer Research Center and the University of California, San Francisco. Dr. Wolf’s clinical research interests include hematologic malignancies, stem cell transplantation, and novel molecules in the treatment of myeloma.
		Todd Zimmerman, MD Assistant Professor of Medicine University of Chicago Dr. Zimmerman completed his medical school at the University of Illinois in Chicago. After completing his training in Internal Medicine at Northwestern University, he went to the University of Chicago for his fellowship in Hematology-Oncology. Currently, Dr. Zimmerman is an Assistant Professor of Medicine at the University of Chicago and an investigator in the Cancer Research Center. He is a member of the American Society of Hematology, the American Society of Hematology and the American Association of Cancer Research. He is actively involved in the Stem Cell Transplant Program as well as drug development for multiple myeloma through both the Phase I and Phase II programs.